Crossmark

Safety, Tolerability and Pharmacokinetic-Pharmacodynamic Relationship of NX210c Peptide in Healthy Elderly Volunteers: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study

Crossref DOI link: https://doi.org/10.1007/s40120-024-00691-w

Published Online: 2024-12-21

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Janus, Annette

Dumas, Daniël

Le Douce, Juliette

Marie, Sébastien

Pasculli, Giuseppe

Bambury, Pauline

Lemarchant, Sighild

Kremer, Philip

Godfrin, Yann
License Information

Text and Data Mining valid from 2024-12-21

Version of Record valid from 2024-12-21
More Information

Article History

Received: 9 October 2024

Accepted: 26 November 2024

First Online: 21 December 2024

Declarations

:

: Daniël Dumas and Philip Kremer are employed by CHDR. Juliette Le Douce, Sébastien Marie, Sighild Lemarchant, and Annette Janus are employed by Axoltis Pharma. Yann Godfrin is the CEO and a shareholder of Axoltis Pharma. Giuseppe Pasculli and Pauline Bambury are employed by InSilicoTrials.

: This clinical study was conducted in full compliance with the protocol, principles of the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines, and the laws and regulations of France and the Netherlands.

Document is current

Any future updates will be listed below